Medicines Evaluation Unit, Langley Building, Wythenshawe Hospital
Welcome,         Profile    Billing    Logout  
 7 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Singh, Dave
TRECOS, NCT06264674: Comparison Between CHF5993 pMDI 200/6/12,5mg HFA-152a VS CHF5993 pMDI 200/6/12,5mg HFA-134a in Subjects With Asthma (Trecos)

Recruiting
3
790
Europe
CHF5993 200/6/12.5 μg pMDI HFA-152a, HFA-152a propellant, Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a, HFA-134a propellant
Chiesi Farmaceutici S.p.A.
Asthma
08/24
09/25
COURSE, NCT04039113 / 2019-001363-67: Tezepelumab COPD Exacerbation Study

Calendar Jan 2024 - Dec 2024: Data from COURSE trial for COPD
Completed
2
337
Europe, Canada, US, RoW
Tezepelumab, Placebo
AstraZeneca, Amgen
Chronic Obstructive Pulmonary Disease (COPD)
11/23
01/24
NCT06166056: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

Recruiting
1/2
45
Europe
CHF6333, CHF6333 Placebo
Chiesi Farmaceutici S.p.A.
Bronchiectasis
06/25
06/25
NCT04769869: A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma

Completed
1
110
Europe
AZD4604 for inhalation via DPI, Placebo for AZD4604 for inhalation via DPI, AZD4604 for IV administration, AZD4604 for oral administration
AstraZeneca
Asthma
01/23
01/23
NCT05195008: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants

Completed
1
72
Europe
BIIB113, BIIB113-Matching Placebo, 11^C]BIO-1819578
Biogen
Healthy Volunteer
07/23
07/23
SPYVAC01, NCT06145178: A Study of Human Cytomegalovirus (HCMV) Vaccine SPYVLP01 With and Without Adjuvants

Recruiting
1
120
Europe
SPYVAC01
SpyBiotech Limited
Cytomegalovirus Infections
04/25
04/25
NCT05965089: A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.

Recruiting
1
58
Europe
Placebo, AX-202
Arxx Therapeutics
Healthy Volunteers, Mild to Moderate Psoriasis
07/24
07/24

Download Options